Overview

Bioequivalence Study to Compare Diclofenac Potassium Coated Tablet (50 mg Diclofenac Potassium) Versus Cataflam® 50 Coated Tablet (50 mg Diclofenac Potassium), in Healthy Subjects Under Fasting Condition

Status:
Completed

Trial end date:
2020-09-16

Target enrollment:

Participant gender:

Summary

Randomized, four-way, four-period, fully-replicated, single oral dose, open-label, crossover, bioequivalence study to compare Diclofenac Potassium coated tablet (50 mg Diclofenac Potassium) versus Cataflam® 50 coated tablet (50 mg Diclofenac Potassium), in healthy subjects under fasting condition

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Pharmactive Ilac Sanayi ve Tic A.S.

Treatments:

Diclofenac